These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 28056988)

  • 41. The impact of cytoreductive nephrectomy on survival outcomes in patients treated with tyrosine kinase inhibitors for metastatic renal cell carcinoma in a real-world cohort.
    Janisch F; Hillemacher T; Fuehner C; D'Andrea D; Meyer CP; Klotzbücher T; Kienapfel C; Vetterlein MW; Kimura S; Abufaraj M; Dahlem R; Shariat SF; Fisch M; Rink M
    Urol Oncol; 2020 Sep; 38(9):739.e9-739.e15. PubMed ID: 32576526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma.
    Day D; Kanjanapan Y; Kwan E; Yip D; Lawrentschuk N; Davis ID; Azad AA; Wong S; Rosenthal M; Gibbs P; Tran B
    Intern Med J; 2016 Nov; 46(11):1291-1297. PubMed ID: 27507629
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.
    Mathieu R; Pignot G; Ingles A; Crepel M; Bigot P; Bernhard JC; Joly F; Guy L; Ravaud A; Azzouzi AR; Gravis G; Chevreau C; Zini L; Lang H; Pfister C; Lechevallier E; Fais PO; Berger J; Vayleux B; Roupret M; Audenet F; Descazeaud A; Rigaud J; Machiels JP; Staehler M; Salomon L; Ferriere JM; Kleinclauss F; Bensalah K; Patard JJ
    Urol Oncol; 2015 Aug; 33(8):339.e9-15. PubMed ID: 26087971
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
    Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
    Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center.
    Hatakeyama S; Yoneyama T; Hamano I; Murasawa H; Narita T; Oikawa M; Hagiwara K; Noro D; Tanaka T; Tanaka Y; Hashimoto Y; Koie T; Ohyama C
    BMC Urol; 2013 Oct; 13():47. PubMed ID: 24125174
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal cell carcinoma with inferior vena cava thrombus: the Hacettepe experience.
    Yazici S; Inci K; Bilen CY; Gudeloglu A; Akdogan B; Ertoy D; Kaynaroglu V; Demircin M; Ozen H
    Urol Oncol; 2010; 28(6):603-9. PubMed ID: 19171489
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy.
    Blute ML; Boorjian SA; Leibovich BC; Lohse CM; Frank I; Karnes RJ
    J Urol; 2007 Aug; 178(2):440-5; discussion 444. PubMed ID: 17561151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Type II papillary histology predicts poor outcome in patients with renal cell carcinoma and vena cava thrombus.
    Kim KH; You D; Jeong IG; Kwon TW; Cho YM; Hong JH; Ahn H; Kim CS
    BJU Int; 2012 Dec; 110(11 Pt B):E673-8. PubMed ID: 22973869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
    Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S
    Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.
    Bex A; Mulders P; Jewett M; Wagstaff J; van Thienen JV; Blank CU; van Velthoven R; Del Pilar Laguna M; Wood L; van Melick HHE; Aarts MJ; Lattouf JB; Powles T; de Jong Md PhD IJ; Rottey S; Tombal B; Marreaud S; Collette S; Collette L; Haanen J
    JAMA Oncol; 2019 Feb; 5(2):164-170. PubMed ID: 30543350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Validation of preoperative variables and stratification of patients to help predict benefit of cytoreductive nephrectomy in the targeted therapy ERA.
    Manley BJ; Kim EH; Vetter JM; Potretzke AM; Strope SA
    Int Braz J Urol; 2017; 43(3):432-439. PubMed ID: 28128914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
    Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Should cytoreductive nephrectomy be performed in patients with metastatic renal cell carcinoma and what is the scientific rationale?].
    Gilbert N; Merseburger AS; Kramer MW
    Urologe A; 2017 May; 56(5):604-609. PubMed ID: 28314973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Hospital Case Volume on Outcomes Following Radical Nephrectomy and Inferior Vena Cava Thrombectomy.
    Freifeld Y; Woldu SL; Singla N; Clinton T; Bagrodia A; Hutchinson R; Lotan Y; Margulis V
    Eur Urol Oncol; 2019 Nov; 2(6):691-698. PubMed ID: 31411983
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma.
    Bhindi B; Graham J; Wells JC; Bakouny Z; Donskov F; Fraccon A; Pasini F; Lee JL; Basappa NS; Hansen A; Kollmannsberger CK; Kanesvaran R; Yuasa T; Ernst DS; Srinivas S; Rini BI; Bowman I; Pal SK; Choueiri TK; Heng DYC
    Eur Urol; 2020 Oct; 78(4):615-623. PubMed ID: 32362493
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
    Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
    Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort.
    Haddad AQ; Wood CG; Abel EJ; Krabbe LM; Darwish OM; Thompson RH; Heckman JE; Merril MM; Gayed BA; Sagalowsky AI; Boorjian SA; Margulis V; Leibovich BC
    J Urol; 2014 Oct; 192(4):1050-6. PubMed ID: 24704115
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.
    Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Pacifici M; Coppa J; Mazzaferro V; de Braud F; Porta C; Escudier B; Procopio G
    PLoS One; 2016; 11(4):e0151662. PubMed ID: 27064898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of cytoreductive surgery in the era of targeted agents.
    Noe A; Stewart GD; Bex A
    Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.